125 related articles for article (PubMed ID: 23487173)
1. Warfarin replacements: good for patients, challenging for laboratories.
Eby CS
Clin Chem; 2013 May; 59(5):732-4. PubMed ID: 23487173
[No Abstract] [Full Text] [Related]
2. Laboratory assessment of novel oral anticoagulants: method suitability and variability between coagulation laboratories.
Helin TA; Pakkanen A; Lassila R; Joutsi-Korhonen L
Clin Chem; 2013 May; 59(5):807-14. PubMed ID: 23378569
[TBL] [Abstract][Full Text] [Related]
3. Point-of-care coagulation testing for assessment of the pharmacodynamic anticoagulant effect of direct oral anticoagulant.
Mani H; Herth N; Kasper A; Wendt T; Schuettfort G; Weil Y; Pfeilschifter W; Linnemann B; Herrmann E; Lindhoff-Last E
Ther Drug Monit; 2014 Oct; 36(5):624-31. PubMed ID: 24577124
[TBL] [Abstract][Full Text] [Related]
4. Measurement of dabigatran and rivaroxaban in primary prevention of venous thromboembolism in 106 patients, who have undergone major orthopedic surgery: an observational study.
Samama MM; Guinet C; Le Flem L; Ninin E; Debue JM
J Thromb Thrombolysis; 2013 Feb; 35(2):140-6. PubMed ID: 23335022
[TBL] [Abstract][Full Text] [Related]
5. Measurement of the direct oral anticoagulants apixaban, dabigatran, edoxaban, and rivaroxaban in human plasma using turbulent flow liquid chromatography with high-resolution mass spectrometry.
Gous T; Couchman L; Patel JP; Paradzai C; Arya R; Flanagan RJ
Ther Drug Monit; 2014 Oct; 36(5):597-605. PubMed ID: 24695356
[TBL] [Abstract][Full Text] [Related]
6. Anticoagulation without monitoring.
Chandler WL
Am J Clin Pathol; 2013 Nov; 140(5):606-7. PubMed ID: 24124137
[No Abstract] [Full Text] [Related]
7. Simultaneous determination of rivaroxaban and dabigatran levels in human plasma by high-performance liquid chromatography-tandem mass spectrometry.
Korostelev M; Bihan K; Ferreol L; Tissot N; Hulot JS; Funck-Brentano C; Zahr N
J Pharm Biomed Anal; 2014 Nov; 100():230-235. PubMed ID: 25173108
[TBL] [Abstract][Full Text] [Related]
8. Laboratory testing for the new oral anticoagulants: a review of current practice.
Favaloro EJ; Bonar R; Butler J; Marsden K
Pathology; 2013 Jun; 45(4):435-7. PubMed ID: 23635821
[No Abstract] [Full Text] [Related]
9. Effects on routine coagulation screens and assessment of anticoagulant intensity in patients taking oral dabigatran or rivaroxaban: guidance from the British Committee for Standards in Haematology.
Baglin T; Keeling D; Kitchen S;
Br J Haematol; 2012 Nov; 159(4):427-9. PubMed ID: 22970737
[No Abstract] [Full Text] [Related]
10. Routine coagulation assays underestimate levels of antithrombin-dependent drugs but not of direct anticoagulant drugs in plasma from patients with cirrhosis.
Potze W; Arshad F; Adelmeijer J; Blokzijl H; van den Berg AP; Porte RJ; Lisman T
Br J Haematol; 2013 Dec; 163(5):666-73. PubMed ID: 24219333
[TBL] [Abstract][Full Text] [Related]
11. Bleeding with dabigatran, rivaroxaban, apixaban. No antidote, and little clinical experience.
Prescrire Int; 2013 Jun; 22(139):155-9. PubMed ID: 23866358
[TBL] [Abstract][Full Text] [Related]
12. Direct oral anticoagulants--pharmacology, drug interactions, and side effects.
Dempfle CE
Semin Hematol; 2014 Apr; 51(2):89-97. PubMed ID: 24861792
[TBL] [Abstract][Full Text] [Related]
13. Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort study.
Abraham NS; Singh S; Alexander GC; Heien H; Haas LR; Crown W; Shah ND
BMJ; 2015 Apr; 350():h1857. PubMed ID: 25910928
[TBL] [Abstract][Full Text] [Related]
14. Practical management of bleeding due to the anticoagulants dabigatran, rivaroxaban, and apixaban.
Fawole A; Daw HA; Crowther MA
Cleve Clin J Med; 2013 Jul; 80(7):443-51. PubMed ID: 23821689
[TBL] [Abstract][Full Text] [Related]
15. Reverse engineering for new oral anticoagulants: non-specific reversal agents and the anticoagulant activity of dabigatran and rivaroxaban.
Levi M
Thromb Haemost; 2012 Aug; 108(2):201-2. PubMed ID: 22739774
[No Abstract] [Full Text] [Related]
16. Assays for measuring rivaroxaban: their suitability and limitations.
Lindhoff-Last E; Samama MM; Ortel TL; Weitz JI; Spiro TE
Ther Drug Monit; 2010 Dec; 32(6):673-9. PubMed ID: 20844464
[TBL] [Abstract][Full Text] [Related]
17. Reversal of new oral anticoagulants.
Battinelli EM
Circulation; 2011 Oct; 124(14):1508-10. PubMed ID: 21969317
[No Abstract] [Full Text] [Related]
18. Use of Thromboelastography (TEG) for Detection of New Oral Anticoagulants.
Dias JD; Norem K; Doorneweerd DD; Thurer RL; Popovsky MA; Omert LA
Arch Pathol Lab Med; 2015 May; 139(5):665-73. PubMed ID: 25927150
[TBL] [Abstract][Full Text] [Related]
19. Risk of gastrointestinal bleeding associated with oral anticoagulants: population based retrospective cohort study.
Chang HY; Zhou M; Tang W; Alexander GC; Singh S
BMJ; 2015 Apr; 350():h1585. PubMed ID: 25911526
[TBL] [Abstract][Full Text] [Related]
20. Influence of dabigatran and rivaroxaban on routine coagulation assays. A nationwide Belgian survey.
Van Blerk M; Bailleul E; Chatelain B; Demulder A; Devreese K; Douxfils J; Jochmans K; Mullier F; Wijns W; Soumali MR; Coucke W; Vernelen K; Van de Walle P
Thromb Haemost; 2015 Jan; 113(1):154-64. PubMed ID: 25231101
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]